Actuate Therapeutics Inc (ACTU)

Currency in USD
1.21
-0.02(-1.63%)
Closed·
1.210.00(0.06%)
·
ACTU is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.211.40
52 wk Range
1.169.22
Key Statistics
Prev. Close
1.23
Open
1.24
Day's Range
1.21-1.4
52 wk Range
1.16-9.22
Volume
255.72K
Average Volume (3m)
194.61K
1-Year Change
-80.2932%
Book Value / Share
0.16
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ACTU Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.98
Upside
+724.59%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Actuate Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 9.98
(+724.59% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy15.00+1,139.67%-MaintainJun 10, 2026
H.C. Wainwright
Buy15.00+1,139.67%-MaintainApr 22, 2026
B.Riley
Buy8.00+561.16%20.00MaintainApr 15, 2026
H.C. Wainwright
Buy15.00+1,139.67%20.00MaintainApr 13, 2026
H.C. Wainwright
Buy20.00+1,552.89%-MaintainJan 15, 2026

Earnings

Latest Release
May 14, 2026
EPS / Forecast
-0.24 / -0.31
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ACTU Income Statement

Compare ACTU to Peers and Sector

Metrics to compare
ACTU
Peers
Sector
Relationship
P/E Ratio
−1.3x−2.4x−0.4x
PEG Ratio
−0.03−0.020.00
Price/Book
7.6x2.3x2.6x
Price / LTM Sales
-17.8x3.0x
Upside (Analyst Target)
-76.0%51.7%
Fair Value Upside
Unlock18.9%8.8%Unlock

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company’s lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.20M5.01%1.45M
Other Institutional Investors
27.51M94.99%33.29M
Public Companies & Retail Investors
0.000.00%0.00
Total
28.71M100.00%34.74M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Bios Equity Partners LP42.00%10,049,99612,160
BIOS Fund III, LP13.77%3,295,2723,987

People Also Watch

4.120
PODC
+1.73%
2.88
NCT
-1.03%
2.86
CAST
-16.13%
0.46
BIYA
-9.93%
13.08
AGMB
+0.38%

FAQ

What Is the Actuate Therapeutics (ACTU) Stock Price Today?

The Actuate Therapeutics stock price today is 1.21 USD.

What Stock Exchange Does Actuate Therapeutics Trade On?

Actuate Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Actuate Therapeutics?

The stock symbol for Actuate Therapeutics is "ACTU."

What Is the Actuate Therapeutics Market Cap?

As of today, Actuate Therapeutics market cap is 28.95M USD.

What Is Actuate Therapeutics's Earnings Per Share (TTM)?

The Actuate Therapeutics EPS (TTM) is -0.98.

When Is the Next Actuate Therapeutics Earnings Date?

Actuate Therapeutics will release its next earnings report on Sep 02, 2026.

From a Technical Analysis Perspective, Is ACTU a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Actuate Therapeutics Stock Split?

Actuate Therapeutics has split 0 times.

How Many Employees Does Actuate Therapeutics Have?

Actuate Therapeutics has 12 employees.

What is the current trading status of Actuate Therapeutics (ACTU)?

As of Jul 12, 2026, Actuate Therapeutics (ACTU) is trading at a price of 1.21 USD, with a previous close of 1.23 USD. The stock has fluctuated within a day range of 1.21 USD to 1.40 USD, while its 52-week range spans from 1.16 USD to 9.22 USD.

What Is Actuate Therapeutics (ACTU) Price Target According to Analysts?

The average 12-month price target for Actuate Therapeutics is 9.98 USD, with a high estimate of 14.91 USD and a low estimate of 5 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +724.59% Upside potential.

What Is the ACTU Premarket Price?

ACTU's last pre-market stock price is 1.32 USD. The pre-market share volume is 10.00, and the stock has decreased by 0.09, or 7.32%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.